| Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: report from the PTLD.Int Survey. | |
| | |
MedLine Citation:
|
PMID: 21183884 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Epstein-Barr virus (EBV) encodes 2 small nonpolyadenylated noncoding RNAs termed EBERs. EBERs are the most common viral transcripts found in EBV-infected cells. In the present study we aimed to examine various aspects of EBER positivity in PTLD patients. MATERIAL/METHODS: We conducted a comprehensive search for the available data by Pubmed and Google Scholar search engines for reports indicating results of EBERs in PTLD patients. Data from 27 previously published studies were included into analysis. Finally, 243 recipients of allograft were included into analysis. RESULTS: One and 5 years survival rates for PTLD patients with EBER-positive results were 61% and 50%, respectively, compared to 55% and 49%, respectively, for EBER-negative PTLD patients. When death specifically due to PTLD was used as the final outcome, EBER-positive PTLD patients had relatively superior outcome; although p-value did not reach the significance level (p=0.09). EBER-positive patients were significantly more likely to develop PTLD lesions of B cell types (vs. T cell type; p=0.018); and early onset PTLD (p<0.001). EBER-positive PTLD patients were significantly more likely to be polymorphic versus monomorphic (p=0.05). EBER-negative PTLD patients were more likely to develop non-Hodgkin PTLD lesions (p<0.001). CONCLUSIONS: We found that PTLD patients with positive results for EBER represent relatively better histopathological features than those in EBER-negative PTLD patients, and the survival rate of EBER-positive PTLD patients is not inferior to that of the EBER-negative subjects. Moreover, they were more likely to represent early onset PTLD of B cell type with polymorphic and Hodgkin-like lesions; and biopsy specimens from different organs were significantly different regarding EBER test results. Future studies with large PTLD populations are needed to confirm our findings. |
| | |
Authors:
|
Morteza Izadi; Saeed Taheri |
Related Documents
:
|
19936334 - The prognostic value of serum chromogranin a and prostate specific antigen in prostate ... 2152694 - Treatment of hormonally refractory cancer of the prostate with antineoplaston as2-1. 7166914 - Serial determinations of carcinoembryonic antigen for early detection of recurrent gast... 21209994 - Applicability of zirconia dental prostheses for metal allergy patients. 10516414 - Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-ass... 1084134 - Early and late results after surgical treatment of preinfarction angina. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Annals of transplantation : quarterly of the Polish Transplantation Society Volume: 15 ISSN: 1425-9524 ISO Abbreviation: Ann. Transplant. Publication Date: 2010 Oct-Dec |
Date Detail:
|
Created Date: 2010-12-24 Completed Date: 2011-04-19 Revised Date: 2012-05-09 |
Medline Journal Info:
|
Nlm Unique ID: 9802544 Medline TA: Ann Transplant Country: Poland |
Other Details:
|
Languages: eng Pagination: 102-9 Citation Subset: IM |
Affiliation:
|
Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. dr.izadi.m@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
B-Lymphocytes
/
virology Epstein-Barr Virus Infections / complications* Herpesvirus 4, Human / genetics* Humans In Situ Hybridization Lymphoproliferative Disorders / mortality, virology* Organ Transplantation / adverse effects* RNA, Viral / analysis Survival Rate |
| Chemical | |
Reg. No./Substance:
|
0/RNA, Viral |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Artificial liver support: quo vadis?
Next Document: Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to you...